e-learning
resources
Barcelona 2013
Monday, 09.09.2013
COPD biomarkers
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Heart-type fatty acid binding protein (H-FABP) and brain natriuretic peptide-fragment (BNP-fragment) in COPD patients with pneumonia
G. Baimakanova, S. Avdeev, A. Chuchalin (Moscow, Russian Federation)
Source:
Annual Congress 2013 –COPD biomarkers
Session:
COPD biomarkers
Session type:
Thematic Poster Session
Number:
2173
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
G. Baimakanova, S. Avdeev, A. Chuchalin (Moscow, Russian Federation). Heart-type fatty acid binding protein (H-FABP) and brain natriuretic peptide-fragment (BNP-fragment) in COPD patients with pneumonia. Eur Respir J 2013; 42: Suppl. 57, 2173
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
The prognostic value of elevated levels of troponin I (Tn I) and heart-type fatty acid binding protein (H-FABP) in hospitalized COPD patients with acute respiratory failure (ARF)
Source: Annual Congress 2012 - COPD exacerbation
Year: 2012
Plasma surfactant protein D (SP-D) in patients (pts) with stable (S) COPD and during COPD acute exacerbation (AE)
Source: Annual Congress 2013 –COPD biomarkers
Year: 2013
COPD: Plasma surfactant protein-D (SPD) concentration as a predictor of acute exacerbations (AE) probability
Source: International Congress 2016 – Features and impact of comorbidities in COPD
Year: 2016
The difference between surfactant protein D (SPD) and C-reactive protein (CRP) levels in patients (pts) with chronic obstructive pulmonary disease acute exacerbations (AE COPD) and community acquired pneumonia (CAP)
Source: International Congress 2014 – Clinical presentations
Year: 2014
Surfactant protein D (SPD) and C-reactive protein (CRP) in patient with low respiratory tract infections (LRTI)
Source: Annual Congress 2013 –Lung infections: a clinical point of view
Year: 2013
COPD: Acute exacerbation (AE) rate and saturation in the patients with different plasma surfactant protein D (SP-D) level
Source: Annual Congress 2013 –COPD mechanisms
Year: 2013
The lipokine, or palmitoleic acid (16:1), is a biomarker of lung function in chronic obstructive pulmonary disease (COPD)
Source: International Congress 2014 – Systemic biomarkers for airway diseases
Year: 2014
Does serum uric acid levels predict in-hospital mortality in severe COPD exacerbations?
Source: International Congress 2015 – COPD: interesting notes
Year: 2015
Surfactant protein D (SPD) like marker of effectiveness in patients (pts) with acute exacerbations (AE) of COPD ofphosphatidylcholine treatment outcomes
Source: International Congress 2015 – Different data in COPD
Year: 2015
Response to the combined therapy in COPD patients (pts) with different plasma surfactant protein D (SPD) level
Source: International Congress 2014 – COPD markers
Year: 2014
LSC - 2019 - Plasma surfactant protein-D (SP-D) as a predictor of COPD severe acute exacerbation (SAE)
Source: International Congress 2019 – Exacerbations of airway diseases
Year: 2019
Matrix metalloproteinase, hyaluronic acid and C-reactive protein: Are they really markers of lung obstruction at COPD but not cardiovascular comorbidity?
Source: International Congress 2015 – Notable abstracts in exacerbations, mechanisms and biomarkers in COPD
Year: 2015
N-terminal-pro-B-type natriuretic peptide (NT-proBNP) in patient with acute exacerbations (AE) of COPD
Source: Annual Congress 2008 - Biomarkers and disease assessment in COPD
Year: 2008
Plasma surfactant protein D (SP-D) and comorbidity rate in patients with COPD
Source: International Congress 2014 – Predictors
Year: 2014
Brain natriuretic peptide (BNP) determination in patients hospitalized for COPD exacerbation
Source: Annual Congress 2008 - Biomarkers and disease assessment in COPD
Year: 2008
Brain natriuretic peptide (BNP) levels during acute exacerbations of COPD – a novel biomarker
Source: Annual Congress 2008 - Mechanisms of respiratory infections: interaction between the pathogen and the host
Year: 2008
Relation of troponin and hert type fatty acid protein (H-FABP) levels to echocardiographic and cardiac infarction injury score (CIS) with patients with prespiratory insufficiency due to COPD attack
Source: Annual Congress 2010 - Pulmonary circulation III
Year: 2010
Plasma surfactant protein D (SP-D) and nutritive status in patients with COPD
Source: Annual Congress 2013 –COPD treatment and others
Year: 2013
Metabolomic signature in COPD. Plasma and lung tissue comparison identify sphingolipids as potential biomakers
Source: International Congress 2014 – Markers
Year: 2014
Serum uric acid levels and uric acid/creatinine ratio in stable COPD patients: Are these parameters efficiently predict risky patients for exacerbation and/or severity of the disease?
Source: International Congress 2016 – Biomarkers and phenotypes of COPD
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept